Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,750 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03742323 | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 6 | PETHEMA FoundationOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02715011 | Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 | 62 | Janssen Research & Development, LLCINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT02481934 | Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma(NK-VS-MM) | completed | Phase 1 | 5 | Joaquín Martínez López, MD, PhDOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02367196 | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | completed | Phase 1 | 60 | CelgeneINDUSTRY | 2 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT03898791 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | completed | Phase 1 | 48 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 5, 2021 | clinicaltrials |
| NCT02992483 | Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | completed | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 3, 2021 | clinicaltrials |
| NCT04178902 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma | terminated | Phase 1 | 8 | AbbVieINDUSTRY | 7 | Jul 26, 2021 | clinicaltrials |
| NCT02765165 | Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 26 | Proximagen, LLCINDUSTRY | 2 | Jul 23, 2021 | clinicaltrials |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | completed | Phase 1 / Phase 2 | 105 | Bristol-Myers SquibbINDUSTRY | 9 | Jul 23, 2021 | clinicaltrials |
| NCT02197247 | Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 6 | Jul 12, 2021 | clinicaltrials |
| NCT03360734 | Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors(GATTO) | completed | Phase 1 | 50 | Glycotope GmbHINDUSTRY | 3 | Jul 12, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT03394937 | Safety of Intranodal ECI-006 in Melanoma Patients | terminated | Phase 1 | 21 | eTheRNA immunotherapiesINDUSTRY | 2 | Jun 21, 2021 | clinicaltrials |
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT02533674 | Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | PharmaMarINDUSTRY | 2 | Jun 11, 2021 | clinicaltrials |
| NCT01188681 | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 79 | Aptevo TherapeuticsINDUSTRY | 5 | Jun 10, 2021 | clinicaltrials |
| NCT03605212 | Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults(FLORET) | terminated | Phase 1 / Phase 2 | 30 | Menarini GroupINDUSTRY | 4 | Jun 3, 2021 | clinicaltrials |
| NCT02143635 | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 8 | May 21, 2021 | clinicaltrials |
| NCT02028117 | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients(OCTAVE) | completed | Phase 1 | 38 | Akamis BioINDUSTRY | 2 | May 13, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT02859324 | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 4 | May 11, 2021 | clinicaltrials |
| NCT03009214 | A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours | completed | Phase 1 | 55 | amcure GmbHINDUSTRY | 2 | May 10, 2021 | clinicaltrials |
| NCT01976741 | Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) | completed | Phase 1 | 168 | BayerINDUSTRY | 7 | May 6, 2021 | clinicaltrials |
| NCT03283202 | Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors | completed | Phase 1 | 35 | CelgeneINDUSTRY | 4 | Apr 29, 2021 | clinicaltrials |
| NCT01857193 | Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | completed | Phase 1 | 132 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 13, 2021 | clinicaltrials |
| NCT04798703 | Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID) | completed | Phase 1 | 20 | Fidia Farmaceutici s.p.a.INDUSTRY | 2 | Mar 17, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT02740270 | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | completed | Phase 1 | 92 | Novartis PharmaceuticalsINDUSTRY | 6 | Feb 21, 2021 | clinicaltrials |
| NCT01927341 | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | completed | Phase 1 / Phase 2 | 53 | PfizerINDUSTRY | 7 | Feb 18, 2021 | clinicaltrials |
| NCT03197714 | Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia | completed | Phase 1 | 9 | Hospital Universitario 12 de OctubreOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | completed | Phase 1 | 85 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 20, 2021 | clinicaltrials |
| NCT02730975 | Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer(ABIFOOD01) | completed | Phase 1 | 42 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT02608125 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | terminated | Phase 1 | 45 | Principia Biopharma, a Sanofi CompanyINDUSTRY | 2 | Dec 24, 2020 | clinicaltrials |
| NCT00715182 | A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer | completed | Phase 1 | 87 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT01468688 | A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 21, 2020 | clinicaltrials |
| NCT01482156 | Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT01735968 | A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | completed | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 21, 2020 | clinicaltrials |
| NCT02703571 | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | terminated | Phase 1 | 95 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT00532389 | Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | completed | Phase 1 | 62 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT00532675 | Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT00880308 | Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | completed | Phase 1 | 103 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01240655 | A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 76 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01242774 | Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01324479 | Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | completed | Phase 1 | 131 | Novartis PharmaceuticalsINDUSTRY | 15 | Dec 19, 2020 | clinicaltrials |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma | terminated | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 19, 2020 | clinicaltrials |
| NCT01487785 | Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT01598077 | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer | completed | Phase 1 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials